1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 153 pages

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 8, 7, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Achaogen Inc
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Lakewood-Amedex Inc
MedImmune LLC
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck and Co Inc
Motif Bio Plc
Nabriva Therapeutics AG
Polyphor Ltd
Sealife PHARMA GMBH
Shionogi and Co Ltd
Tetraphase Pharmaceuticals Inc
TGV-Inhalonix Inc
The Medicines Company
Theravance Biopharma Inc
Wockhardt Ltd
Zavante Therapeutics Inc
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(amikacin sulfate + fosfomycin) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(avibactam + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(avibactam sodium + aztreonam lysine) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(meropenem+ vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
AA-139 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Aerucin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
alalevonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
amikacin sulfate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
arbekacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
cefepime + zidebactam - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
cefiderocol - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
delafloxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
eravacycline - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
fosfomycin tromethamine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
iclaprim mesylate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Levonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
MEDI-3902 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Nu-2 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Panaecin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
panobacumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
POL-7001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
suvratoxumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
telavancin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Viritron VDX - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News and Press Releases
Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates
Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016
Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
Apr 11, 2016: VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments
Apr 04, 2016: Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference
Feb 26, 2016: Pendopharm Launches Vibativ In Canada
Feb 26, 2016: Pendopharm Launches Vibativ In Canada
Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck and Co Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi and Co Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2017
Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H1 2017
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2017
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016’, provides in depth analysis on DNA Gyrase ...

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide ...

Burkholderia Infections - Pipeline Review, H2 2016

Burkholderia Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Burkholderia Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides ...

Q Fever - Pipeline Review, H2 2016

November 2016 $ 2000

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.